AG-EE 623 ZW

• Hypoglycemic Agents
• Meglitinides
• ATC:A10BX02

• AG-EE 388 ZW
• AG-EE 623 ZW
• Prandin
• Repaglinida [Inn-Spanish]
• Repaglinide [Usan]
• Repaglinidum [Inn-Latin]

• No information avaliable

C₂₇H₃₆N₂O₄

http://www.rxlist.com/cgi/generic/prandin.htm

AG-EE_623_ZW FDA

AG-EE_623_ZW MSDS

W. Grell et al., PCT Int. pat. Appl. WO 93 00,337

452.586 g/mol

130-131 ^oC

No information avaliable

Solid

5.798

Tablet

For the treatment of Type II diabetes mellitus.

Repaglinide is an oral blood glucose-lowering drug of the meglitinide class used in the management of type 2 diabetes mellitus (also known as non-insulin dependent diabetes mellitus or NIDDM). Repaglinide lowers blood glucose levels by stimulating the release of insulin from the pancreas. This action is dependent upon functioning beta cells in the pancreatic islets. Insulin release is glucose-dependent and diminishes at low glucose concentrations.

Rapid (bioavailability is 56%)

LD₅₀ >1 g/kg (rat) (W. Grell)

PATIENT INFORMATION

Patients should be informed of the potential risks and advantages of Repaglinide (PRANDIN) and of alternative modes of therapy. They should also be informed about the importance of adherence to dietary instructions, of a regular exercise program, and of regular testing of blood glucose and HbA1c. The risks of hypoglycemia, its symptoms and treatment, and conditions that predispose to its development and concomitant administration of other glucose-lowering drugs should be explained to patients and responsible family members. Primary and secondary failure should also be explained.

Patients should be instructed to take Repaglinide before meals (2, 3, or 4 times a day preprandially). Doses are usually taken within 15 minutes of the meal but time may vary from immediately preceding the meal to as long as 30 minutes before the meal. Patients who skip a meal (or add an extra meal) should be instructed to skip (or add) a dose for that meal.

Humans and other mammals